Biotech (688177.SH): Ashuride® (golimumab injection) obtained drug registration certificate

^{Zhitong Finance App News, Biotech (688177.SH) issued an announcement. The company recently received the “Drug Registration Certificate” for golimumab injection (BAT2506, trade name: Ashulide®) approved and issued by the National Drug Administration (“NMPA”).}

According to reports, BAT2506 is a golimumab biosimilar developed by the company according to the NMPA, the US Food and Drug Administration, and the European Medicines Agency's biosimilar guidelines. Golimumab is an antibody targeting TNF-α. It can specifically bind soluble and transmembrane human TNF-α with high affinity, block the binding of TNF-α to its receptor TNFR, thereby inhibiting the activity of TNF-α. Ashuride ^{® is the first golimumab biosimilar drug in China. Its approval for marketing helps enhance} the market competitiveness of the company's products and has a positive effect on the company's business development.